Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus brentuximab vedotin vs brentuximab vedotin in relapsed/refractory or ASCT-ineligible classical Hodgkin lymphoma
jRCT2080223830Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in classical Hodgkin lymphoma (cHL) comparing Nivolumab + brentuximab vedotin with Brentuximab vedotin monotherapy (2 arms). Started Mar 2018; status: completed.
02
Drugs
nivolumabbrentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on jRCT2080223830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223830.